Nanoform, a company specialising in medicine performance-enhancing, has entered into a pre-clinical development partnership with the plasma-derived therapy unit of Takeda Pharmaceuticals.
The goal of the collaboration is to develop novel plasma-derived therapeutic formulations to treat rare conditions.
As part of the deal, Nanoform will provide non-GMP nanomaterial to Takeda, which the company will utilise in its in vivo studies.
Results from these studies will likely be available in early 2025.
The development collaboration will endeavour to accelerate the journey of medicines for rare diseases to clinic, and then onto the market.
“Direct nanoforming of biologics is a promising new approach to allow more life-changing large-molecule medicines to reach the market,” commented the CEO of Nanoform, Dr Edward Haeggström. “We look forward to entering in vivo studies together with Takeda and expanding our already very positive relationship.”
Nanoform Biologics’ nanoforming technology can deliver large-molecule drug particles of tuneable size and morphology, while retaining biological activity.
The technology can be applied across the biologics field, from 1 to 150KDa, to enable novel routes of delivery, enhance drug loading, tailor release profiles and engineer new drug combinations.
